Show simple item record

dc.contributor.authorHouston, Isaac B.
dc.contributor.authorPeter, Cyril J.
dc.contributor.authorMitchell, Amanda C.
dc.contributor.authorStraubhaar, Juerg R.
dc.contributor.authorRogaev, Evgeny I.
dc.contributor.authorAkbarian, Schahram
dc.date2022-08-11T08:08:29.000
dc.date.accessioned2022-08-23T15:56:37Z
dc.date.available2022-08-23T15:56:37Z
dc.date.issued2013-01-01
dc.date.submitted2013-07-26
dc.identifier.citationNeuropsychopharmacology. 2013 Jan;38(1):183-97. doi: 10.1038/npp.2012.78. <a href="http://dx.doi.org/10.1038/npp.2012.78">Link to article on publisher's site</a>
dc.identifier.issn0006-3223 (Linking)
dc.identifier.doi10.1038/npp.2012.78
dc.identifier.pmid22643929
dc.identifier.urihttp://hdl.handle.net/20.500.14038/30009
dc.description.abstractMany cellular constituents in the human brain permanently exit from the cell cycle during pre- or early postnatal development, but little is known about epigenetic regulation of neuronal and glial epigenomes during maturation and aging, including changes in mood and psychosis spectrum disorders and other cognitive or emotional disease. Here, we summarize the current knowledge base as it pertains to genome organization in the human brain, including the regulation of DNA cytosine methylation and hydroxymethylation, and a subset of (altogether >100) residue-specific histone modifications associated with gene expression, and silencing and various other functional chromatin states. We propose that high-resolution mapping of epigenetic markings in postmortem brain tissue or neural cultures derived from induced pluripotent cells (iPS), in conjunction with transcriptome profiling and whole-genome sequencing, will increasingly be used to define the molecular pathology of specific cases diagnosed with depression, schizophrenia, autism, or other major psychiatric disease. We predict that these highly integrative explorations of genome organization and function will provide an important alternative to conventional approaches in human brain studies, which mainly are aimed at uncovering group effects by diagnosis but generally face limitations because of cohort size.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=22643929&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1038/npp.2012.78
dc.subjectBrain Chemistry
dc.subjectDNA Methylation
dc.subjectEpigenesis, Genetic
dc.subjectHumans
dc.subjectMental Disorders
dc.subjectCell and Developmental Biology
dc.subjectMental Disorders
dc.subjectMolecular and Cellular Neuroscience
dc.subjectNeuroscience and Neurobiology
dc.subjectPsychiatry
dc.subjectPsychiatry and Psychology
dc.titleEpigenetics in the human brain
dc.typeJournal Article
dc.source.journaltitleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
dc.source.volume38
dc.source.issue1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/243
dc.identifier.contextkey4352254
html.description.abstract<p>Many cellular constituents in the human brain permanently exit from the cell cycle during pre- or early postnatal development, but little is known about epigenetic regulation of neuronal and glial epigenomes during maturation and aging, including changes in mood and psychosis spectrum disorders and other cognitive or emotional disease. Here, we summarize the current knowledge base as it pertains to genome organization in the human brain, including the regulation of DNA cytosine methylation and hydroxymethylation, and a subset of (altogether >100) residue-specific histone modifications associated with gene expression, and silencing and various other functional chromatin states. We propose that high-resolution mapping of epigenetic markings in postmortem brain tissue or neural cultures derived from induced pluripotent cells (iPS), in conjunction with transcriptome profiling and whole-genome sequencing, will increasingly be used to define the molecular pathology of specific cases diagnosed with depression, schizophrenia, autism, or other major psychiatric disease. We predict that these highly integrative explorations of genome organization and function will provide an important alternative to conventional approaches in human brain studies, which mainly are aimed at uncovering group effects by diagnosis but generally face limitations because of cohort size.</p>
dc.identifier.submissionpathfaculty_pubs/243
dc.contributor.departmentProgram in Molecular Medicine
dc.contributor.departmentDepartment of Psychiatry, Brudnick Neuropsychiatric Research Institute
dc.source.pages183-97


This item appears in the following Collection(s)

Show simple item record